Objective: To explore the influence of GATA-1 on expression of EpoR in bone marrow CD71+ cells of rat model with high altitude polycythemia (HAPC).
Methods: Forty-eight male SD rats were randomly divided into normal control and HAPC model group. HAPC model was established at the altitude of 4 300 meters in the natural environment, and verified by bone marrow cell counts and hematological parameters. Myeloid CD71+ cells were separated by the density gradient centrifugation combined with magnetic activated cell sorting. The expression of EpoR on cell membrane was detected by flow cytometry and cell immunofluorescence. The expression changes of GATA-1 and EpoR mRNA and protein were detected by Q-PCR and Western blot, respectively. CD71+ cells were cultured under normoxia and hypoxia, respectively. After transfection for 96 h, the optimal interference sequence GATA-1 shRNA1 was selected. And the mRNA and protein expression level of GATA-1 and EpoR were detected by Q-PCR and Western blot respectively.
Results: The animal model with HAPC was established successfully and comfirmed by the bone marrow cell counting and the hematologic parameters in comparison with that of the normal control. EpoR expression on the myeloid CD71+ cell membrane in HAPC group was significantly higher than that in normal control (P<0.05). The expression of GATA-1 and EpoR in myeloid CD71+ cells of HAPC group was higher than that in control group (P<0.05). The mRNA and protein expression of GATA-1 and EpoR in two groups positively correlated (control group, r=0.929, P<0.01, r=0.802, P<0.05; HAPC group, r=0.822, P<0.05, r=0.839, P<0.01). However, the mRNA and protein expression of EpoR at normoxia and hypoxia was significantly lower than that in negative control group after interfernce with GATA-1 shRNA1 for 96 h (P<0.05). And the expression of GATA-1 and EpoR under hypoxia was higher than that in normoxia.
Conclusion: The effect of GATA-1 on EpoR expression may be correlated with the pathogenesis of HAPC.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.7534/j.issn.1009-2137.2016.03.045 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Cellular therapy for the peripheral arterial disease treatment: Protocol for a systematic review and meta-analysis.
PLoS One
January 2025
Department of Nursing and Podiatry, University of Malaga, Malaga, Spain.
Cellular therapy is a promising treatment option for Peripheral Arterial Disease (PAD). Different cell types can be used to regenerate and repair tissues affected by PAD. Many studies have proposed the use of stem cells, such as mesenchymal stem cells, or even mononuclear cells isolated from peripheral blood or bone marrow, to treat PAD.
View Article and Find Full Text PDFUltra-compact quintuple-band terahertz metamaterial biosensor for enhanced blood cancer diagnostics.
PLoS One
January 2025
Faculty of Engineering (FOE), Multimedia University (MMU), Cyberjaya, Selangor, Malaysia.
Cancer and its diverse variations pose one of the most significant threats to human health and well-being. One of the most aggressive forms is blood cancer, originating from bone marrow cells and disrupting the production of normal blood cells. The incidence of blood cancer is steadily increasing, driven by both genetic and environmental factors.
View Article and Find Full Text PDFKidney Disease and Hematopoietic Stem Cell Transplantation.
Kidney360
January 2025
Centro Hospitalar Universitário de Coimbra, Nephrology Department, 3004 Coimbra, Portugal.
Hematopoietic stem cell transplantation (HSCT) is a potentially curative therapy for patients with hematologic malignancies and certain solid tumors and nonmalignant hematologic conditions. Both acute kidney injury (AKI) and chronic kidney disease (CKD) occur commonly after HSCT and are associated with significant morbidity and mortality. AKI and CKD in this setting may result from direct effects of the transplant or be caused by pretransplant bone marrow conditioning regimens and/or nephrotoxic agents administered in the post-transplant period.
View Article and Find Full Text PDFShared Local Oncology Care After Allogeneic Hematopoietic Cell Transplantation: A Randomized Clinical Trial.
JAMA Oncol
January 2025
Division of Hematologic Malignancies, Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.
Importance: Although sharing care with local oncologists after allogeneic hematopoietic cell transplantation (HCT) has been proposed for patients living far from HCT centers, it is not known whether a shared strategy is safe or improves patient quality of life (QOL).
Objective: To determine the efficacy and safety of sharing follow-up care after HCT between the HCT specialty center and local oncologists.
Design, Setting, And Participants: This was a multicenter collaborative randomized clinical trial of patients undergoing HCT at Dana-Farber Cancer Institute (DFCI)-a high volume HCT center in Boston (Massachusetts)-and 8 local oncology practices.
'Nomadic' Hematopoietic Stem Cells Navigate the Embryonic Landscape.
Stem Cell Rev Rep
January 2025
Department of Integrative Biology, Gene Therapy Laboratory, School of Bio Sciences and Technology, Vellore Institute of Technology, Vellore, TN, 632 014, India.
Hematopoietic stem cells are a unique population of tissue-resident multipotent cells with an extensive ability to self-renew and regenerate the entire lineage of differentiated blood cells. Stem cells reside in a highly specialized microenvironment with surrounding supporting cells, forming a complex and dynamic network to preserve and maintain their function. The survival, activation, and quiescence of stem cells are largely influenced by niche-derived signals, with aging niche contributing to a decline in stem cell function.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!